Skip to main
SKIN
SKIN logo

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Beauty Health Co. has demonstrated a positive financial outlook with a 4Q23 revenue of $96.8 million, surpassing both prior estimates of $95.2 million and $88.0 million, primarily driven by strong performance in consumables. The average selling price (ASP) of total systems saw a notable increase of approximately 20% quarter-over-quarter, reaching $28.8K, which exceeded earlier estimates of $24.3K, attributed to a higher mix of direct sales. Despite the EBITDA guidance being back-end weighted, the overall trends in revenue growth and improved ASP indicate strong demand and operational efficiency, which may enhance the company’s growth trajectory moving forward.

Bears say

Beauty Health has reported a significant decline in core delivery system placements, which dropped over 30% year-over-year and quarter-over-quarter, falling well short of earlier estimates. This decrease raises concerns regarding future consumables sales, which are crucial for achieving the company's profitability goals in 2024, particularly as demand is essential for sustaining financial health. Furthermore, management's guidance for 1Q24 sales and adjusted EBITDA is notably below previous estimates, indicating potential challenges in meeting full-year financial targets and necessitating a substantial margin improvement in the latter half of the year.

SKIN has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Buy based on their latest research and market trends.

According to 3 analysts, SKIN has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.